Mercer Global Advisors
SYRE icon

Mercer Global Advisors’s Spyre Therapeutics SYRE Stock Holding History

Mercer Global Advisors’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.32M Buy
71,145
+54
+0.1% +$3.94K 0.01% 772
2026
Q1 		$3.59M Sell
71,091
-35,225
-33% -$1.33M 0.01% 913
2025
Q4 		$3.48M Sell
106,316
-348
-0.3% -$9.09K 0.01% 854
2025
Q3 		$1.79M Buy
106,664
+522
+0.5% +$8.51K ﹤0.01% 1084
2025
Q2 		$1.59M Buy
+106,142
New +$1.57M ﹤0.01% 982

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Mercer Global Advisors's SYRE Position: Q2 2026 in Review

Mercer Global Advisors increased its Spyre Therapeutics (SYRE) stake by 0.08% in Q2 2026, buying an estimated $3.94K and bringing the position to 71,145 shares worth $6.32M. The position accounts for 0.01% of the portfolio, ranked #772.

Mercer Global Advisors first reported a position in SYRE in Q2 2025 and has held it in 5 quarters since. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Mercer Global Advisors held 71,145 shares of Spyre Therapeutics worth $6.32M as of Q2 2026.
  • Mercer Global Advisors bought 54 Spyre Therapeutics shares in Q2 2026, an estimated $3.94K.
  • Spyre Therapeutics made up 0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #772 holding.
  • Mercer Global Advisors first reported a position in Spyre Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.